Metastatic melanoma Trials in Chicago, United States
Conditions / Metastatic melanoma / Chicago, United States
Metastatic melanoma has been the subject of sustained clinical investigation across multiple research sites.
30 total trials for this combination
Showing top 10 of 30 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01134614 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | ACTIVE_NOT_RECRUITING | — |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | RECRUITING | PHASE2 |
| NCT01134614 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | ACTIVE_NOT_RECRUITING | — |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | RECRUITING | — |
| NCT01134614 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | ACTIVE_NOT_RECRUITING | — |
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | RECRUITING | PHASE3 |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | RECRUITING | PHASE3 |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | RECRUITING | — |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | COMPLETED | PHASE1/PHASE2 |